ADMA Biologics, Inc. (ADMA)
Valuation Overview•Is ADMA Biologics, Inc. Overvalued or Undervalued?
Trading at a discount to intrinsic cash flow value, implying pessimistic long-term market expectations.
High-quality fundamentals with a strong composite quality score of 89/100, backed by robust profitability and solvency.
Analysts remain bullish, forecasting further upside expansion with consensus targets suggesting solid gains.
Verdict: High-quality compounder, with growth as the only relative weakness.
Wall Street is highly bullish, projecting significant upside alongside robust expected earnings growth. However, capital return yields remain modest, driven predominantly by aggressive share repurchases.
Returns capital exclusively via buybacks — no active dividend
ADMA exhibits elite business quality, driven by exceptional capital efficiency and highly lucrative margins (highlighted by a massive 36.0% ROIC). This is backed by a fortress balance sheet, holding significant net cash ($8M) and minimal debt risk.
The company is driving exceptional top-line expansion (49.0% 3Y CAGR) paired with stable bottom-line earnings. This growth is supported by elite operational efficiency, sustaining an impressive 42.1% operating margin.
| Financial Metric | Trend (12Q) | Latest Qtr | 1Y Growth | 3Y CAGR | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| Revenue | $114.5M | +19.6% | +49.0% | +64.6% | +53.2% | |
| EBITDA | $58.3M | — | — | — | — | |
| Net Income | $45.3M | -25.7% | — | — | — | |
| EPS (Diluted) | $0.19 | -25.9% | — | — | — | |
| Free Cash Flow | $55.7M | -74.7% | — | — | — |
| Metric | TTM | 3Y Avg | 5Y Avg | 10Y Avg |
|---|---|---|---|---|
| Gross Margin | 61.3% | 47.8% | 33.5% | -4.8% |
| Operating Margin | 42.1% | 26.2% | -3.8% | -100.4% |
| Net Margin | 32.4% | 21.4% | -13.4% | -117.3% |
| FCF Margin | 21.2% | 10.9% | -34.1% | -144.4% |
| Quarter | EPS Est. | EPS Act. | Surprise | EPS | Rev |
|---|---|---|---|---|---|
| Q2'26Latest | $0.19 | $0.19 | -1.7% | ||
| Q1'26 | $0.18 | $0.20 | +8.1% | ||
| Q4'25 | $0.16 | $0.16 | +0.0% | ||
| Q3'25 | $0.14 | $0.15 | +7.1% | ||
| Q2'25 | $0.16 | $0.14 | -12.5% | ||
| Q1'25 | $0.15 | $0.14 | -6.7% | ||
| Q4'24 | $0.13 | $0.15 | +15.4% | ||
| Q3'24 | $0.08 | $0.13 | +62.5% |
Total return is -54.2% (1Y), lagging the benchmark by -79.2%
| Period | Total Return | vs S&P 500 (Alpha) | Dividend Contribution |
|---|---|---|---|
| YTD | -53.5% | -62.8% | — |
| 1Y | -54.2% | -79.2% | — |
| 3YCAGR | +28.7% | +9.7% | — |
| 5YCAGR | +37.0% | +23.8% | — |
| 10YCAGR | +1.7% | -11.7% | — |
The S&P 500 is at 31.3x trailing P/E — Expensive relative to historical averages.
Quick answers to common questions about ADMA Biologics, Inc. (ADMA) valuation, health, and returns.
ADMA Biologics, Inc. is estimated to be undervalued under our discounted cash flow framework. relative multiples indicate the stock is Fair versus peers compared to industry peers. undervalued (implying +120.8% upside to DCF intrinsic value of $18.35)
ADMA Biologics, Inc. has multiple valuation anchors: DCF Intrinsic Value: $18.35 | Peer Relative Fair Value: $7.96 | Wall Street Analyst Target: $21.00 (implying +152.7% upside). A convergence of these signals offers higher conviction.
ADMA Biologics, Inc. displays excellent financial health with a composite quality score of 89/100, supported by a Altman Z-Score of 9.9 (safe zone), Piotroski F-Score of 5/9, Return on Invested Capital (ROIC) of 36.0%.
ADMA Biologics, Inc. returns capital via buybacks instead of dividends, carrying a 1.7% buyback yield and reducing outstanding shares by +0.6% in the last 12 months.
ADMA Biologics, Inc.'s current growth trajectory is Decelerating. The company achieved +19.6% 1Y revenue growth and -25.9% 1Y EPS growth, compared to its 3Y revenue CAGR of +49.0%.
Wall Street consensus is Buy based on 10 analysts, beating EPS expectations in 58% of recent quarters with a -1-quarter streak. The consensus price target represents a +152.7% change from current levels.
Investment risks for ADMA Biologics, Inc. include: -62.7% 1-year max drawdown. Volatility risk is characterized by a beta of 1.07x.
No. These computations are purely quantitative model outputs for informational purposes. They do not account for qualitative management shifts or macro events. Always consult a licensed RIA before buying or selling shares.
Disclaimer: This page is for informational purposes only and does not constitute financial advice. All valuation models, scores, and target estimates are automated computations under stated assumptions and should not be relied upon as the sole basis for any investment decision.